
The Novosibirsk Center for Virology and Biotechnology "Vector" has submitted documents to the Ministry of HEALTH of the Russian Federation for the registration of another drug for CORONAVIRUS "EpiVakKorona-N", follows from the data of the state register of medicines. Previously, Vector has developed the EpiVacCoron vaccine against covid-19 .
The drug was named "EpiVacCorona-N", it was developed using peptide antigens - artificially synthesized short fragments of viral proteins. With their help, the immunity of a vaccinated person must learn to recognize virus cells. The same technology was used to create the first vaccine.
In the registry data, it is noted that the form of the drug is a suspension for intramuscular injection, the volume of one dose is 0.5 ml.
In April, the Ministry of Health of the Russian Federation issued permission to conduct the first and second phases of clinical trials of the EpiVacCorona-N vaccine. They started on April 8 and will end on September 30. The department reported that 300 volunteers would take part in them.
Vector CEO Rinat Maksyutov noted that the development of a new version of the vaccine is needed in order to enter large-scale production. According to him, there are no significant differences between the drugs, they differ in the technological features of production.
The EpiVacCorona coronavirus vaccine was registered on October 13, 2020. It became the second Russian vaccine against COVID-19. Clinical trials of the drug began in early December. The drug entered civilian circulation on January 1, 2021.
"EpiVacCoron" was created on the basis of artificially synthesized short fragments of viral proteins. With their help, the immunity of a vaccinated person must learn to recognize virus cells.
Read on RBC Pro Nassim Taleb - RBC: "I see a threat more serious than a pandemic"six answer options